Search

Your search keyword '"Nikolic, Natasa"' showing total 14 results
Start Over Author "Nikolic, Natasa" Publication Year Range Last 3 years
14 results on '"Nikolic, Natasa"'

4. Predictive value of admission glycemia in diabetics with pulmonary embolism compared to non-diabetic patients

Author

Jovanovic, Ljiljana, Rajkovic, Milena, Subota, Vesna, Subotic, Bojana, Dzudovic, Boris, Matijasevic, Jovan, Benic, Marija, Salinger, Sonja, Simovic, Stefan, Miloradovic, Vladimir, Kovacevic, Tamara Preradovic, Kos, Ljiljana, Neskovic, Aleksandar, Kafedzic, Srdjan, Nikolic, Natasa Markovic, Bozovic, Bjanka, Bulatovic, Nebojsa, and Obradovic, Slobodan

Published
2022
Full Text
View/download PDF

5. Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

Author

Gmizic, Ivana I, primary, Barac, Aleksandra, additional, Todorovic, Nevena, additional, Sabanovic, Milos, additional, Kekic, Natalija, additional, Boskovic, Nikola, additional, Vujovic, Ankica, additional, Nikolic, Natasa, additional, Knezevic, Natasa, additional, Milosevic, Ivana, additional, and Stevanovic, Goran, additional

Published
2024
Full Text
View/download PDF

6. Time‐dependent reduction in oxidative capacity among cultured myotubes from spinal cord injured individuals

Author

Stevanovic, Stanislava, primary, Dalmao‐Fernandez, Andrea, additional, Mohamed, Derya, additional, Nyman, Tuula A., additional, Kostovski, Emil, additional, Iversen, Per Ole, additional, Savikj, Mladen, additional, Nikolic, Natasa, additional, Rustan, Arild C., additional, Thoresen, G. Hege, additional, and Kase, Eili T., additional

Published
2024
Full Text
View/download PDF

8. Prevalence of Carcinogenic Genotypes of HPV-Infected Women in a Ten-Year Period (2014–2023) in Vojvodina, Serbia.

Author

Nikolic, Natasa, Basica, Branka, Strbac, Mirjana, Terzic, Lidija, Patic, Aleksandra, Kovacevic, Gordana, Velicki, Radmila, Petrovic, Dusan, Mandic, Aljosa, and Petrovic, Vladimir

Subjects
HUMAN papillomavirus, GENOTYPES, AGE groups, CANCER-related mortality, CERVICAL cancer, GENITAL warts
Abstract

Background and Objectives: Human papillomavirus (HPV) infection and its etiological role in the development of cervical cancer are well established. The cervical cancer mortality rate in Serbia is one of the highest among European countries, and this cancer is the second-leading cause of death in Serbian women aged from 15 to 44. Materials and Methods: This retrospective study was conducted at the Institute of Public Health of Vojvodina. A total of 10,062 cervical specimens from Serbian women were collected and HPV tested in ten years. The study patients were divided into five age groups. HPV genotype testing was performed using a commercial kit to detect 14 high-risk (HR) HPV genotypes. Additionally, cervix cytology data have been available for patients tested in 2022 and 2023. Results: An overall positive rate was found in 43.3% of patients (4356/10,062). A single HPV infection (62.1%) was the main infection pattern. The most frequent HR HPV genotypes were HPV 16, 31, 52, 56, 39, and 51, comprising 62.3% of the detected genotypes, including multiple infections. A significant difference was noted in the HPV prevalence across the different age groups, with a bimodal distribution of HPV infection. The highest prevalence was recorded in the age group ≤ 30 and those after 61 years. Women diagnosed with high-grade squamous intraepithelial lesions (HSIL) were significantly older compared to others. HR HPV is the most prevalent in patients with HSIL cytological findings (76.5%). The most common type, according to age-specific distribution and cytological findings, was HR HPV 16. Conclusions: This study provides comprehensive data on HR HPV distribution among Serbian women, which can serve as a basis for subsequent monitoring of genotypic distribution. It is particularly significant considering they are missing in the updated ICO/IARC Report for Serbia, and the cervical cancer mortality rate in Serbia is one of the highest among European countries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Prognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism

Author

Jovanovic, Ljiljana, primary, Subota, Vesna, additional, Rajkovic, Milena, additional, Subotic, Bojana, additional, Dzudovic, Boris, additional, Novcic, Natasa, additional, Matijasevic, Jovan, additional, Miric, Milica, additional, Salinger, Sonja, additional, Nikolic, Natasa Markovic, additional, Nikolic, Maja, additional, Miloradovic, Vladimir, additional, Kos, Ljiljana, additional, Kovacevic-Preradovic, Tamara, additional, and Obradovic, Slobodan, additional

Published
2023
Full Text
View/download PDF

14. Prognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism

Author

Jovanovic, Ljiljana, Subota, Vesna, Rajkovic, Milena, Subotic, Bojana, Dzudovic, Boris, Novcic, Natasa, Matijasevic, Jovan, Miric, Milica, Salinger, Sonja, Nikolic, Natasa Markovic, Nikolic, Maja, Miloradovic, Vladimir, Kos, Ljiljana, Kovacevic-Preradovic, Tamara, and Obradovic, Slobodan

Abstract

In patients with pulmonary embolism (PE), the D-dimer assay is commonly utilized as part of the diagnostic workup, but data on D-dimer for early risk stratification and short-term mortality prediction are limited. The purpose of this study was to determine D-dimer levels as a predictive biomarker of PE outcomes in younger (<50 years of age) compared to older patients. We conducted retrospective analysis for 930 patients diagnosed with PE between 2015 and 2019 as part of the Serbian University Multicenter Pulmonary Embolism Registry (SUPER).All patients had D-dimer levels measured within 24 hours of hospital admission. The primary outcome was mortality at 30 days or during hospitalization. Patients were categorized into two groups based on age (≤ 50 and >50 years of age). Younger patients constituted 20.5% of the study cohort. Regarding all-cause mortality, 5.2% (10/191)of patients died in group under the 50 years of age; the short-term all-causemortality was 12.4% (92/739) in older group.We have found that there was significant difference in plasma D-dimer level between patients ≤ 50 years of age and older group (>50), p= 0.006.D-dimer plasma level had good predictive value for the primary outcome in younger patients (c-statistics 0.710; 95% CI, 0.640-0.773; p<0.031). The optimal cutoff level for D-dimer to predict PE-cause death in patients aged > 50 years was found to be 8.8 mg/l FEU(c-statistics 0,580; 95% CI 0.544-0.616; p=0.049). In younger PE patients, D-dimer levels have good prognostic performance for 30-day all-cause mortalityand concentrations above 6.3 mg/l FEU are associated with increased risk of death. D-dimer in patients aged over 50 years does not have predictive ability for all-caused short-term mortality. The relationship between D-dimer and age in patients with PE may need further evaluation.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results